Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...
Rezolute, Inc.: Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming ...
United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
GeneDx CEO wants genetic testing for every newborn
GeneDx CEO Katherine Stueland likes the potential of newborn testing, but she says her Stamford, Connecticut, company is still studying the idea. A potential challenge: Insurers would have to embrace ...
Nasdaq6d
Rezolute, Inc. Reports Positive DMC Review of sunRIZE Study for Ersodetug in Infants with Hyperinsulinism
Study enrollment completion is anticipated in the ... effective at treating hypoglycemia due to any congenital or acquired form of HI. The Phase 3 sunRIZE study is a multi-center, randomized ...
Education Department removes nonbinary gender ID option from financial aid form
Students will no longer be able to identify themselves as nonbinary when applying for federal financial aid, the Trump ...
College aid form completion recovers in Michigan after debacle, but key issue remains
FAFSA process recovers, but officials said more work needs to be done to get more Michigan students to complete the FAFSA and enroll in college.
Open enrollment to play big role in District 719’s finances, facilities
The Prior Lake-Savage Area School Board once again had a lengthy discussion about its Dec. 12 decision to close open enrollment to the statutory minimum at all grade levels during a study session ...
Palatin Technologies, Inc.: Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
planadviser.com4d
Study Finds Most Corporate Retirement Plans Have Regulatory or Fiduciary Violations
According to Abernathy Daley 401k Consultants, more than 600,000 American companies could be at risk of fines, legal ...
Moleculin Biotech reaches agreement to amend investor warrants
Houston-based Moleculin Biotech, Inc., currently trading at $0.80 and showing a market capitalization of $2.4 million, has entered into an agreement with an investor to modify certain terms of ...
TMCnet2h
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds momentum with both Fast Track and Orphan Drug Designations.